安非他酮缓释片治疗抑郁症对照研究  

A control study of bupropion sustained-release in the treatment of depression

作　　者：郭建雄[1] 杜文佳[1] 王西林[1] 李婷[1] 徐贵云[1] 

机构地区：[1]广州市脑科医院,广东广州510370

出　　处：《临床心身疾病杂志》2007年第4期323-324,共2页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨安非他酮缓释片治疗抑郁症的临床疗效及安全性。方法将72例抑郁症患者随机分为两组各36例,研究组口服安非他酮治疗,对照组口服氟西汀治疗,观察6w。于治疗前及治疗1w、2w、4w、6w末采用汉密顿抑郁量表、汉密顿焦虑量表、临床总体印象量表、副反应量表评定临床疗效及不良反应。结果研究组有效率83.3%,对照组为86.1%,两组有效率比较差异无显著性(P>0.05)。两组各量表评分,治疗1w起均较治疗前有显著或极显著性下降(P<0.05或0.01),2w末起均有极显著性下降(P均<0.01),但同期两组间比较差异无显著性(P均>0.05)。两组不良反应均较轻微,发生率比较无显著性差异。结论盐酸安非他酮缓释片治疗抑郁症疗效与氟西汀相当,安全性高,依从性好。Objective To explore the clinical curative effects and safety of bupropion sustained-release in the treatment of depression. Methods 72 patients with depression were randomly assigned to research group （n = 36） orally taking bupropion and cotrol group（n=36） taking fluoxetinf for 6 weeks. The clinical efficacies were assessed with the Hamilton Depression Scale（HAMD）, the Hamilton Anxiety Scale（HAMA） and the Clinical Global Impresion（CGI）, and adverse effects with the Treatment Emergent Symptoms Scale（TESS） before treatment and at the end of the 1st, 2nd ,3rd , and 4th week treatment. Results Effective rates were 83.3% of the research group and 86.1% of the control group, which showed no significant difference（P〉0.05）. Since the 1st week all scales＇ scores of both group significantly or very significantly decreased（P〈0.05 or 0.01） ,and since the end of the 2nd week very significantly decreased（P〈0.01） compared with pre-treatment,but there was no significant difference in synchronization intergroup comparison （P〉0. 05）. The adverse effects of both groups were mild and the incidence of the adverse effects had no significant difference. Conclusion Bupropion extentab is equivalent to fluoxetine and has higher safety and better compliance in depression.

关 键 词：抑郁症 安非他酮 氟西汀 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R749.053[医药卫生—临床医学]